PAMAM-PEG-Angiopep, complexed with TRAIL plasmid, displayed excellent blood–brain-barrier penetration ability and a favorable biodistribution and pharmacodynamic profile in vivo, thus emerging as a promising nanocarrier for targeted therapies in glioma [112]. The gene discussed is TNFSF10; the disease is central nervous system cancer.